ReviewFrontiers in oncology2026

Feasibility, reliability, and clinical value of genomic assay on pre-therapeutic biopsy for endocrine receptor-positive HER2-negative early breast cancer.

Gilles Houvenaeghel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.